Financial Survey: Kiora Pharmaceuticals (KPRX) and Its Rivals

Kiora Pharmaceuticals (NASDAQ:KPRX) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Kiora Pharmaceuticals to similar companies based on the strength of its earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Risk & Volatility

Kiora Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals’ competitors have a beta of -3.80, meaning that their average share price is 480% less volatile than the S&P 500.

Profitability

This table compares Kiora Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Kiora Pharmaceuticals Competitors	-2,381.34%	-218.59%	-15.77%

Insider & Institutional Ownership

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Kiora Pharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1	0	0	0	1.00
Kiora Pharmaceuticals Competitors	7803	13893	25800	1039	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.19%. Given Kiora Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Kiora Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02 million	-$10.84 million	-0.56
Kiora Pharmaceuticals Competitors	$3.54 billion	$3.16 billion	552.63

Kiora Pharmaceuticals’ competitors have higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Kiora Pharmaceuticals competitors beat Kiora Pharmaceuticals on 9 of the 13 factors compared.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.